Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Alkermes | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Alkermes

Revenues up 8% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alkermes

3Q Revenues: $135.9 million (+8%)

3Q Earnings: $16.3 million (loss of $14.8 million 3Q11)

YTD Revenues: $412.1 million (+59%)

YTD Earnings: $22.0 million (loss of $50.3 million YTD11)

Comments: Net sales of Vivitrol were $15.9 million, up 50%. Manufacturing and royalty revenues (M&R) were $118.3 million in the quarter, up 5%, and $364 million YTD, up 67%. Risperdal Consta and Invega Sustenna/Xeplion M&R revenues were $52.5 million in the quarter, up 10%. M&R revenues from Ampyra/Fampyra were $18.4 million, up 74%, and royalty revenues from Bydureon were $5.3 million, compared to $0.3 million in 3Q12. Other M&R revenues, which includes contract manufacturing operations, were $25.4 million in the quarter. R&D revenue was $1.7 million, down 24%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters